基于 RNA-seq 的 EHMT2 在乳腺癌中的转录组功能分析。
RNA-seq based transcriptome analysis of EHMT2 functions in breast cancer.
机构信息
Korea Research Institute of Bioscience and Biotechnology, Daejeon, 34141, Republic of Korea.
Korea Research Institute of Bioscience and Biotechnology, Daejeon, 34141, Republic of Korea; Department of Functional Genomics, Korea University of Science and Technology, Daejeon, 34316, Republic of Korea.
出版信息
Biochem Biophys Res Commun. 2020 Apr 9;524(3):672-676. doi: 10.1016/j.bbrc.2020.01.128. Epub 2020 Feb 4.
For breast cancer treatment, hormone therapy is effective for hormone receptor-positive breast cancer but not for TNBC (triple-negative breast cancer). Thus, many researchers have attempted to identify more effective therapeutic candidates for all subtypes of breast cancer. In this study, we established an RNA-seq analytical pipeline to analyze the subtype-specific functions of EHMT2 in the MB231 and MCF7 cell lines. After EHMT2 knockdown, we identified subtype-specific DEGs (differentially expressed genes) and overlapping DEGs. Through GO (Gene Ontology) analysis, GSEA (gene set enrichment analysis), and KEGG (Kyoto Encyclopedia of Genes and Genomes) analysis using the DEGs, we identified the subtype-specific functions of EHMT2 in the MB231 and MCF7 cell lines. Therefore, herein, we suggest that EHMT2 is an attractive therapeutic target for the treatment of all types of breast cancer.
对于乳腺癌治疗，激素疗法对激素受体阳性乳腺癌有效，但对三阴性乳腺癌（TNBC）无效。因此，许多研究人员试图为所有亚型的乳腺癌确定更有效的治疗候选物。在这项研究中，我们建立了一个 RNA-seq 分析管道，以分析 EHMT2 在 MB231 和 MCF7 细胞系中的亚型特异性功能。在 EHMT2 敲低后，我们鉴定了亚型特异性的 DEGs（差异表达基因）和重叠的 DEGs。通过使用 DEGs 的 GO（基因本体论）分析、GSEA（基因集富集分析）和 KEGG（京都基因与基因组百科全书）分析，我们鉴定了 EHMT2 在 MB231 和 MCF7 细胞系中的亚型特异性功能。因此，我们认为 EHMT2 是治疗所有类型乳腺癌的有吸引力的治疗靶点。
Zotero 插件